Lucinactant for the prevention of respiratory distress syndrome in premature infants

References

• Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J. Dis. Child. 97(5, Part 1), 517–523 (1959).
   PubMedGoogle Scholar
• Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N. Engl. J. Med. 330(21), 1476–1480 (1994).
   PubMed Web of Science ®Google Scholar
• Halliday HL. Surfactants: past, present and future. J. Perinatol. 28(Suppl. 1), S47–S56 (2008).
   PubMed Web of Science ®Google Scholar
• Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Statement 12(2), 1–24 (1994).
   Google Scholar
• Betz P, Nerlich A, Wilske J et al. Determination of fetal age by immunohistochemical estimation of surfactant-producing alveolar type II cells. Forensic Sci. Int. 53(2), 193–202 (1992).
   PubMed Web of Science ®Google Scholar
• Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 254(5031), 566–568 (1991).
   PubMed Web of Science ®Google Scholar
• Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. 2, CD000511 (2000).
   Google Scholar
• Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst. Rev. 4, CD006069 (2007).
   Google Scholar
• Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr. Dev. Pathol. 12(4), 253–274 (2009).
   PubMed Web of Science ®Google Scholar
• Clark JC, Wert SE, Bachurski CJ et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl Acad. Sci. USA 92(17), 7794–7798 (1995).
   PubMed Web of Science ®Google Scholar
• Hamvas A, Nogee LM, Mallory GB Jr et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J. Pediatr. 130(2), 231–239 (1997).
   PubMed Web of Science ®Google Scholar
• Cole FS, Hamvas A, Nogee LM. Genetic disorders of neonatal respiratory function. Pediatr. Res. 50(2), 157–162 (2001).
   PubMed Web of Science ®Google Scholar
• Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N. Engl. J. Med. 328(6), 406–410 (1993).
   PubMed Web of Science ®Google Scholar
• Ma J, Koppenol S, Yu H, Zografi G. Effects of a cationic and hydrophobic peptide, KL4, on model lung surfactant lipid monolayers. Biophys. J. 74(4), 1899–1907 (1998).
   PubMed Web of Science ®Google Scholar
• Cochrane CG. Surfactant protein B and mimic peptides in the function of pulmonary surfactant. FEBS Lett. 430(3), 424; discussion 425 (1998).
   Web of Science ®Google Scholar
• Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1(8159), 55–59 (1980).
   PubMed Web of Science ®Google Scholar
• Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. 1, CD001079 (2010).
   Google Scholar
• Tooley WH, Clements JA, Muramatsu K, Brown CL, Schlueter MA. Lung function in prematurely delivered rabbits treated with a synthetic surfactant. Am. Rev. Respir. Dis. 136(3), 651–656 (1987).
   PubMedGoogle Scholar
• Vincent JS, Revak SD, Cochrane CD, Levin IW. Interactions of model human pulmonary surfactants with a mixed phospholipid bilayer assembly: Raman spectroscopic studies. Biochemistry 32(32), 8228–8238 (1993).
   PubMed Web of Science ®Google Scholar
• Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst. Rev. 2, CD000144 (2001).
   Google Scholar
• Revak SD, Merritt TA, Hallman M et al. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants. Pediatr. Res. 29(5), 460–465 (1991).
   PubMed Web of Science ®Google Scholar
• Nilsson G, Gustafsson M, Vandenbussche G et al. Synthetic peptide-containing surfactants–evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur. J. Biochem. 255(1), 116–124 (1998).
   PubMedGoogle Scholar
• Gustafsson M, Vandenbussche G, Curstedt T, Ruysschaert JM, Johansson J. The 21-residue surfactant peptide (LysLeu4)4Lys(KL4) is a transmembrane alpha-helix with a mixed nonpolar/polar surface. FEBS Lett. 384(2), 185–188 (1996).
   PubMed Web of Science ®Google Scholar
• Donn SM. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin. Investig. Drugs 14(3), 329–334 (2005).
   PubMed Web of Science ®Google Scholar
• Wolfson MR, Wu J, Hubert TL, Gregory TJ, Mazela J, Shaffer TH. Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS. Pediatr. Res. 72(4), 375–383 (2012).
   PubMed Web of Science ®Google Scholar
• Andersson S, Kheiter A, Merritt TA. Oxidative inactivation of surfactants. Lung 177(3), 179–189 (1999).
   PubMed Web of Science ®Google Scholar
• Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr. Res. 39(6), 947–952 (1996).
   PubMed Web of Science ®Google Scholar
• Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr. Res. 50(1), 44–49 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Z, Baatz JE, Holm BA, Notter RH. Content-dependent activity of lung surfactant protein B in mixtures with lipids. Am. J. Physiol. Lung Cell Mol. Physiol. 283(5), L897–L906 (2002).
   PubMed Web of Science ®Google Scholar
• Moya FR, Gadzinowski J, Bancalari E et al.; International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 115(4), 1018–1029 (2005).
   PubMed Web of Science ®Google Scholar
• Sinha SK, Lacaze-Masmonteil T, Valls i Soler A et al.; Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115(4), 1030–1038 (2005).
   PubMed Web of Science ®Google Scholar
• Bailey S, Hendricks-Munoz K, Mally P. Animal origins of surfactant: a survey of neonatologists’ perceptions and practices regarding parent information sharing. AJOB Primary Res. 2(1), 26–33 (2011).
   Google Scholar
• Sarkar S, Donn SM. Do neonatologists and parents share the same concerns about animal-derived pharmaceutical agents? J. Neonat. Perinat. Med. 4(3), 235–239 (2011).
   Google Scholar
• Merritt TA, Kheiter A, Cochrane CG. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr. Res. 38(2), 211–217 (1995).
   PubMed Web of Science ®Google Scholar
• Surfaxin® (lucinactant) intratracheal suspension, prescribing information, Discovery Laboratories, PA, USA (2012).
   Google Scholar
• Gastiasoro-Cuesta E, Alvarez-Diaz FJ, Rey-Santano C, Arnaiz-Renedo A, Loureiro-Gonzalez B, Valls-i-Soler A. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. Pediatrics 117(2), 295–303 (2006).
   PubMed Web of Science ®Google Scholar
• Revak SD, Merritt TA, Cochrane CG et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr. Res. 39(4 Pt 1), 715–724 (1996).
   PubMedGoogle Scholar
• Romero EJ, Moya FR, Tuvim MJ, Alcorn JL. Interaction of an artificial surfactant in human pulmonary epithelial cells. Pediatr. Pulmonol. 39(2), 167–177 (2005).
   PubMed Web of Science ®Google Scholar
• Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. 2, CD001079 (2000).
   Google Scholar
• Donn SM, Sinha SK. Lucinactant in neonatal respiratory distress syndrome: an evidence-based review of its effectiveness on clinical outcomes. Core Evidence 2(4), 233–240 (2008).
   Google Scholar
• Piehl E, Fernandez-Bustamante A. Lucinactant for the treatment of respiratory distress syndrome in neonates. Drugs Today 48(9), 587–593 (2012).
   PubMed Web of Science ®Google Scholar
• Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82(5), 683–691 (1988).
   PubMed Web of Science ®Google Scholar
• Guardia CG, Moya FR, Sinha SK et al. Re-intubation and risk of morbidity and mortality in preterm infants after surfactant replacement therapy. J. Neonatal-Perinatal Med. 4, 101–109 (2011).
   Google Scholar
• Moya FR, Hoffman DR, Zhao B, Johnston JM. Platelet-activating factor in surfactant preparations. Lancet 341(8849), 858–860 (1993).
   PubMed Web of Science ®Google Scholar
• Mazela J, Merritt TA, Terry MH, Gregory TJ, Blood AB. Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress. Pediatr. Res. doi:10.1038/pr.2012.46 (2012) (Epub ahead of print).
   Google Scholar
• Johnson M, Rodriguez L, Pearson R, Rairkar M. KL4 surfactant (Aerosurf) retains surface activity after aerosolization. E-PAS 61, 6292–6297 (2007).
   Google Scholar
• Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J. Aerosol Med. Pulm. Drug Deliv. 23(5), 303–309 (2010).
   PubMed Web of Science ®Google Scholar
• Sinha SK, Donn SM. Aerosolized lucinactant: a potential alternative to intratracheal surfactant replacement therapy. Expert Opin. Pharmacother. 9(3), 475–478 (2008).
   PubMed Web of Science ®Google Scholar
• Yeh TF, Lin HC, Chang CH et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 121(5), e1310–e1318 (2008).
   PubMed Web of Science ®Google Scholar